Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study

Abstract Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectivel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, Yu Nakamura, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Tomoyuki Kaneko, Shigenori Kakutani, Mayuko Tokunaga, Yukari Uemura, Yusuke Sato, Tetsuya Fujimura, Hiroshi Fukuhara, Yutaka Enomoto, Hiroaki Nishimatsu, Satoru Takahashi, Haruki Kume
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aaeb739adafe4a6cac9b81ab3a654824
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aaeb739adafe4a6cac9b81ab3a654824
record_format	dspace
spelling	oai:doaj.org-article:aaeb739adafe4a6cac9b81ab3a6548242021-12-02T16:36:36ZPrognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study10.1038/s41598-021-95061-z2045-2322https://doaj.org/article/aaeb739adafe4a6cac9b81ab3a6548242021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95061-zhttps://doaj.org/toc/2045-2322Abstract Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance status (PS), with progression-free survival, cancer-specific survival, and overall survival. The Cox proportional hazards model was used for univariate and multivariable analyses. The AGR was dichotomized as < 0.95 and ≥ 0.95 based on receiver operating characteristic curve analysis. After excluding 26 cases with missing data from the total of 176 cases, 109 (73%) patients experienced disease progression, 75 (50%) died from UC, and 6 (4%) died of other causes (median survival = 12 months). Multivariate analyses identified PS ≥ 2 and pretreatment AGR < 0.95 as independent poor prognostic factors for all endpoints. Furthermore, a prognostic risk model incorporating these two variables achieved a relatively high concordance index for all endpoints. This is the first report to evaluate the significance of AGR in advanced UC. Pretreatment AGR < 0.95 may serve as a prognostic marker for advanced UC treated with pembrolizumab.Satoru TaguchiTaketo KawaiTohru NakagawaYu NakamuraJun KameiDaisuke ObinataKenya YamaguchiTomoyuki KanekoShigenori KakutaniMayuko TokunagaYukari UemuraYusuke SatoTetsuya FujimuraHiroshi FukuharaYutaka EnomotoHiroaki NishimatsuSatoru TakahashiHaruki KumeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Satoru Taguchi Taketo Kawai Tohru Nakagawa Yu Nakamura Jun Kamei Daisuke Obinata Kenya Yamaguchi Tomoyuki Kaneko Shigenori Kakutani Mayuko Tokunaga Yukari Uemura Yusuke Sato Tetsuya Fujimura Hiroshi Fukuhara Yutaka Enomoto Hiroaki Nishimatsu Satoru Takahashi Haruki Kume Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
description	Abstract Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance status (PS), with progression-free survival, cancer-specific survival, and overall survival. The Cox proportional hazards model was used for univariate and multivariable analyses. The AGR was dichotomized as < 0.95 and ≥ 0.95 based on receiver operating characteristic curve analysis. After excluding 26 cases with missing data from the total of 176 cases, 109 (73%) patients experienced disease progression, 75 (50%) died from UC, and 6 (4%) died of other causes (median survival = 12 months). Multivariate analyses identified PS ≥ 2 and pretreatment AGR < 0.95 as independent poor prognostic factors for all endpoints. Furthermore, a prognostic risk model incorporating these two variables achieved a relatively high concordance index for all endpoints. This is the first report to evaluate the significance of AGR in advanced UC. Pretreatment AGR < 0.95 may serve as a prognostic marker for advanced UC treated with pembrolizumab.
format	article
author	Satoru Taguchi Taketo Kawai Tohru Nakagawa Yu Nakamura Jun Kamei Daisuke Obinata Kenya Yamaguchi Tomoyuki Kaneko Shigenori Kakutani Mayuko Tokunaga Yukari Uemura Yusuke Sato Tetsuya Fujimura Hiroshi Fukuhara Yutaka Enomoto Hiroaki Nishimatsu Satoru Takahashi Haruki Kume
author_facet	Satoru Taguchi Taketo Kawai Tohru Nakagawa Yu Nakamura Jun Kamei Daisuke Obinata Kenya Yamaguchi Tomoyuki Kaneko Shigenori Kakutani Mayuko Tokunaga Yukari Uemura Yusuke Sato Tetsuya Fujimura Hiroshi Fukuhara Yutaka Enomoto Hiroaki Nishimatsu Satoru Takahashi Haruki Kume
author_sort	Satoru Taguchi
title	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
title_short	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
title_full	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
title_fullStr	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
title_full_unstemmed	Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
title_sort	prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/aaeb739adafe4a6cac9b81ab3a654824
work_keys_str_mv	AT satorutaguchi prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT taketokawai prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT tohrunakagawa prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT yunakamura prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT junkamei prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT daisukeobinata prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT kenyayamaguchi prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT tomoyukikaneko prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT shigenorikakutani prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT mayukotokunaga prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT yukariuemura prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT yusukesato prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT tetsuyafujimura prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT hiroshifukuhara prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT yutakaenomoto prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT hiroakinishimatsu prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT satorutakahashi prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy AT harukikume prognosticsignificanceofthealbumintoglobulinratioforadvancedurothelialcarcinomatreatedwithpembrolizumabamulticenterretrospectivestudy
_version_	1718383650427371520

Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study

Ejemplares similares